Home
Random
Nearby
Log in
Settings
Donate
About Wikidata
Disclaimers
Search
(Q34569899)
Watch
English
Trastuzumab: hopes and realities
scientific article
In more languages
edit
Statements
instance of
scholarly article
1 reference
stated in
Europe PubMed Central
PubMed ID
11902499
retrieved
3 August 2017
review article
1 reference
stated in
Europe PubMed Central
title
Trastuzumab: hopes and realities
(English)
1 reference
stated in
Europe PubMed Central
PubMed ID
11902499
retrieved
3 August 2017
main subject
trastuzumab
1 reference
based on heuristic
inferred from title
author name string
Brian Leyland-Jones
series ordinal
1
1 reference
stated in
Europe PubMed Central
PubMed ID
11902499
retrieved
3 August 2017
publication date
1 March 2002
1 reference
stated in
Europe PubMed Central
PubMed ID
11902499
retrieved
3 August 2017
published in
Lancet Oncology Commission
1 reference
stated in
Europe PubMed Central
PubMed ID
11902499
retrieved
3 August 2017
volume
3
1 reference
stated in
Europe PubMed Central
PubMed ID
11902499
retrieved
3 August 2017
page(s)
137-144
1 reference
stated in
Europe PubMed Central
PubMed ID
11902499
retrieved
3 August 2017
issue
3
1 reference
stated in
Europe PubMed Central
PubMed ID
11902499
retrieved
3 August 2017
cites work
Treatment of breast cancer
1 reference
stated in
Crossref
reference URL
https://api.crossref.org/works/10.1016%2FS1470-2045%2802%2900676-9
retrieved
7 January 2021
based on heuristic
inferred from DOI database lookup
Cancer statistics, 1999.
1 reference
stated in
Crossref
reference URL
https://api.crossref.org/works/10.1016%2FS1470-2045%2802%2900676-9
retrieved
7 January 2021
based on heuristic
inferred from DOI database lookup
Monoclonal antibody therapy for solid tumors
1 reference
stated in
Crossref
reference URL
https://api.crossref.org/works/10.1016%2FS1470-2045%2802%2900676-9
retrieved
7 January 2021
based on heuristic
inferred from DOI database lookup
Breast cancer therapies in development. A review of their pharmacology and clinical potential.
1 reference
stated in
Crossref
reference URL
https://api.crossref.org/works/10.1016%2FS1470-2045%2802%2900676-9
retrieved
7 January 2021
based on heuristic
inferred from DOI database lookup
Toward checkmate: biology and breast cancer therapy for the new millennium
1 reference
stated in
Crossref
reference URL
https://api.crossref.org/works/10.1016%2FS1470-2045%2802%2900676-9
retrieved
7 January 2021
based on heuristic
inferred from DOI database lookup
Untangling the ErbB signalling network
1 reference
stated in
Crossref
reference URL
https://api.crossref.org/works/10.1016%2FS1470-2045%2802%2900676-9
retrieved
7 January 2021
based on heuristic
inferred from DOI database lookup
Human breast cancer: correlation of relapse and survival with amplification of the HER-2/neu oncogene
1 reference
stated in
Crossref
reference URL
https://api.crossref.org/works/10.1016%2FS1470-2045%2802%2900676-9
retrieved
7 January 2021
based on heuristic
inferred from DOI database lookup
Studies of the HER-2/neu proto-oncogene in human breast and ovarian cancer
1 reference
stated in
Crossref
reference URL
https://api.crossref.org/works/10.1016%2FS1470-2045%2802%2900676-9
retrieved
7 January 2021
based on heuristic
inferred from DOI database lookup
The HER-2/neu oncogene in breast cancer: prognostic factor, predictive factor, and target for therapy.
1 reference
stated in
Crossref
reference URL
https://api.crossref.org/works/10.1016%2FS1470-2045%2802%2900676-9
retrieved
7 January 2021
based on heuristic
inferred from DOI database lookup
Determination of Her-2/Neu status in breast carcinoma: comparative analysis of immunohistochemistry and fluorescent in situ hybridization
1 reference
stated in
Crossref
reference URL
https://api.crossref.org/works/10.1016%2FS1470-2045%2802%2900676-9
retrieved
7 January 2021
based on heuristic
inferred from DOI database lookup
c-erbB-2 over-expression in amplified and non-amplified breast carcinoma samples
1 reference
stated in
Crossref
reference URL
https://api.crossref.org/works/10.1016%2FS1470-2045%2802%2900676-9
retrieved
7 January 2021
based on heuristic
inferred from DOI database lookup
Estrogen-dependent, tamoxifen-resistant tumorigenic growth of MCF-7 cells transfected with HER2/neu
1 reference
stated in
Crossref
reference URL
https://api.crossref.org/works/10.1016%2FS1470-2045%2802%2900676-9
retrieved
7 January 2021
based on heuristic
inferred from DOI database lookup
HER-2/neu amplification in benign breast disease and the risk of subsequent breast cancer
1 reference
stated in
Crossref
reference URL
https://api.crossref.org/works/10.1016%2FS1470-2045%2802%2900676-9
retrieved
7 January 2021
based on heuristic
inferred from DOI database lookup
HER2. a 'predictive factor' ready to use in the daily management of breast cancer patients?
1 reference
stated in
Crossref
reference URL
https://api.crossref.org/works/10.1016%2FS1470-2045%2802%2900676-9
retrieved
7 January 2021
based on heuristic
inferred from DOI database lookup
Humanization of an anti-p185HER2 antibody for human cancer therapy
1 reference
stated in
Crossref
reference URL
https://api.crossref.org/works/10.1016%2FS1470-2045%2802%2900676-9
retrieved
7 January 2021
based on heuristic
inferred from DOI database lookup
Monoclonal antibody therapy of human cancer: Taking the HER2 protooncogene to the clinic
1 reference
stated in
Crossref
reference URL
https://api.crossref.org/works/10.1016%2FS1470-2045%2802%2900676-9
retrieved
7 January 2021
based on heuristic
inferred from DOI database lookup
Differential responses of human tumor cell lines to anti-p185HER2 monoclonal antibodies
1 reference
stated in
Crossref
reference URL
https://api.crossref.org/works/10.1016%2FS1470-2045%2802%2900676-9
retrieved
7 January 2021
based on heuristic
inferred from DOI database lookup
Remission of human breast cancer xenografts on therapy with humanized monoclonal antibody to HER-2 receptor and DNA-reactive drugs
1 reference
stated in
Crossref
reference URL
https://api.crossref.org/works/10.1016%2FS1470-2045%2802%2900676-9
retrieved
7 January 2021
based on heuristic
inferred from DOI database lookup
Inhibitory effects of combinations of HER-2/neu antibody and chemotherapeutic agents used for treatment of human breast cancers
1 reference
stated in
Crossref
reference URL
https://api.crossref.org/works/10.1016%2FS1470-2045%2802%2900676-9
retrieved
7 January 2021
based on heuristic
inferred from DOI database lookup
Multinational study of the efficacy and safety of humanized anti-HER2 monoclonal antibody in women who have HER2-overexpressing metastatic breast cancer that has progressed after chemotherapy for metastatic disease
1 reference
stated in
Crossref
reference URL
https://api.crossref.org/works/10.1016%2FS1470-2045%2802%2900676-9
retrieved
7 January 2021
based on heuristic
inferred from DOI database lookup
Use of chemotherapy plus a monoclonal antibody against HER2 for metastatic breast cancer that overexpresses HER2.
1 reference
stated in
Crossref
reference URL
https://api.crossref.org/works/10.1016%2FS1470-2045%2802%2900676-9
retrieved
7 January 2021
based on heuristic
inferred from DOI database lookup
Herceptin alone or in combination with chemotherapy in the treatment of HER2-positive metastatic breast cancer: pivotal trials
1 reference
stated in
Crossref
reference URL
https://api.crossref.org/works/10.1016%2FS1470-2045%2802%2900676-9
retrieved
7 January 2021
based on heuristic
inferred from DOI database lookup
First-line, single-agent Herceptin(trastuzumab) in metastatic breast cancer: a preliminary report
1 reference
stated in
Crossref
reference URL
https://api.crossref.org/works/10.1016%2FS1470-2045%2802%2900676-9
retrieved
7 January 2021
based on heuristic
inferred from DOI database lookup
Recommendations for HER2 testing in the UK.
1 reference
stated in
Crossref
reference URL
https://api.crossref.org/works/10.1016%2FS1470-2045%2802%2900676-9
retrieved
7 January 2021
based on heuristic
inferred from DOI database lookup
Retrospective analysis of the safety of Herceptin immunotherapy in metastatic breast cancer
1 reference
stated in
Crossref
reference URL
https://api.crossref.org/works/10.1016%2FS1470-2045%2802%2900676-9
retrieved
7 January 2021
based on heuristic
inferred from DOI database lookup
Mechanism of action of anti-HER2 monoclonal antibodies
1 reference
stated in
Crossref
reference URL
https://api.crossref.org/works/10.1016%2FS1470-2045%2802%2900676-9
retrieved
7 January 2021
based on heuristic
inferred from DOI database lookup
Weekly trastuzumab and paclitaxel therapy for metastatic breast cancer with analysis of efficacy by HER2 immunophenotype and gene amplification.
1 reference
stated in
Crossref
reference URL
https://api.crossref.org/works/10.1016%2FS1470-2045%2802%2900676-9
retrieved
7 January 2021
based on heuristic
inferred from DOI database lookup
Clinical activity of trastuzumab and vinorelbine in women with HER2-overexpressing metastatic breast cancer
1 reference
stated in
Crossref
reference URL
https://api.crossref.org/works/10.1016%2FS1470-2045%2802%2900676-9
retrieved
7 January 2021
based on heuristic
inferred from DOI database lookup
Phase II study of weekly intravenous recombinant humanized anti-p185HER2 monoclonal antibody in patients with HER2/neu-overexpressing metastatic breast cancer
1 reference
stated in
Crossref
reference URL
https://api.crossref.org/works/10.1016%2FS1470-2045%2802%2900676-9
retrieved
7 January 2021
based on heuristic
inferred from DOI database lookup
Phase II study of receptor-enhanced chemosensitivity using recombinant humanized anti-p185HER2/neu monoclonal antibody plus cisplatin in patients with HER2/neu-overexpressing metastatic breast cancer refractory to chemotherapy treatment
1 reference
stated in
Crossref
reference URL
https://api.crossref.org/works/10.1016%2FS1470-2045%2802%2900676-9
retrieved
7 January 2021
based on heuristic
inferred from DOI database lookup
Identifiers
DOI
10.1016/S1470-2045(02)00676-9
1 reference
stated in
Europe PubMed Central
PubMed ID
11902499
retrieved
3 August 2017
PubMed ID
11902499
1 reference
stated in
Europe PubMed Central
PubMed ID
11902499
retrieved
3 August 2017
Sitelinks
Wikipedia
(0 entries)
edit
Wikibooks
(0 entries)
edit
Wikinews
(0 entries)
edit
Wikiquote
(0 entries)
edit
Wikisource
(0 entries)
edit
Wikiversity
(0 entries)
edit
Wikivoyage
(0 entries)
edit
Wiktionary
(0 entries)
edit
Multilingual sites
(0 entries)
edit
